What is Precigen?
Precigen Inc. operates as a discovery and clinical-stage biopharmaceutical entity dedicated to the advancement of precision medicine. By leveraging sophisticated gene and cell therapy technologies, the organization targets complex disease states across three primary pillars: immuno-oncology, autoimmune disorders, and infectious diseases. The company maintains a dual-segment operational structure, encompassing both its core Biopharmaceuticals division and its Exemplar segment, which collectively facilitate the translation of scientific discovery into viable clinical applications. Through its focus on precision technology, Precigen aims to address significant unmet medical needs, positioning itself as a critical player in the next generation of targeted therapeutic interventions.
How much funding has Precigen raised?
Precigen has raised a total of $129.4M across 1 funding round:
Stock Offering
$129.4M
Stock Issuance/Offering (2021): $129.4M, investors not publicly disclosed
Key Investors in Precigen
Precigen
Undisclosed investor participating in the funding round.
What's next for Precigen?
With the successful acquisition of $129.4M, Precigen is strategically positioned to scale its clinical development programs and refine its manufacturing capabilities. The firm is expected to prioritize the advancement of its lead candidates through rigorous regulatory milestones, while simultaneously expanding its research footprint in immuno-oncology. By optimizing its operational efficiency and leveraging its existing intellectual property, Precigen intends to enhance its competitive advantage in the biopharmaceutical sector. Future growth will likely be driven by the successful transition of its pipeline assets from early-stage discovery to late-stage clinical trials, ultimately aiming to deliver transformative outcomes for patients suffering from chronic and life-threatening conditions.
See full Precigen company page
